AstraZeneca PLC (AZN)

AZN (NYSE:Drugs) EQUITY
$29.51
pos +0.58
+2.00%
Today's Range: 29.22 - 29.63 | AZN Avg Daily Volume: 7,415,400
Last Update: 02/23/17 - 3:59 PM EST
Volume: 4,791,923
YTD Performance: 6.19%
Open: $29.24
Previous Close: $28.92
52 Week Range: $25.55 - $35.04
Oustanding Shares: 2,530,000,000
Market Cap: 73,395,300,000
6-Month Chart
TheStreet Ratings Grade for AZN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 2 2
Moderate Buy 0 0 0 0
Hold 1 1 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.50 1.50 2.00 2.00
Latest Dividend: 0.93
Latest Dividend Yield: 4.72%
Dividend Ex-Date: 02/15/17
Price Earnings Ratio: 13.01
Price Earnings Comparisons:
AZN Sector Avg. S&P 500
13.01 21.00 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.11% -2.17% -12.90%
GROWTH 12 Mo 3 Yr CAGR
Revenue -5.30 -0.10 -0.04
Net Income 20.50 0.30 0.10
EPS 23.60 0.40 0.11
Earnings for AZN:
EBITDA 5.60B
Revenue 23.00B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.32 $0.42 $1.79 $1.85
Number of Analysts 1 1 2 3
High Estimate $0.32 $0.42 $1.83 $2.00
Low Estimate $0.32 $0.42 $1.75 $1.57
Prior Year $0.95 $0.83 $4.31 $1.79
Growth Rate (Year over Year) -66.32% -49.40% -58.47% 3.17%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Biotech Buoyed by Deal Talk Real Money Pro($)

M&A activity is in a serious upswing, and here are some names to watch.
These companies show signs of a change of direction.
Bullish
Dec 09, 2016 | 7:28 AM EST
AZN was upgraded from Market Perform to Outperform, Leerink Partners said. $34 price target. Pullback has created a buying opportunity ...
Stocks in the health care sector seem to have no underpinnings whatsoever.

Cempra Is Ready to Run Real Money Pro($)

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
There's a price to pay for low expectations.

Columnist Conversations

The SPDR S&P Biotech ETF (XBI) was trading in a four month symmetrical triangle before it broke out o...
Join me later today as I bring back Toni Hanser to a webinar.  Toni has been away for awhile recovering f...
Here is a well defined zone to look for buy triggers against...defining the risk below it! View Char...
this is the FOURTH big winner we have booked on Apple since December. SOLD AAPL APR 135 CALL AT 4.50 (in ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.